The Cancer Prevention and Control Research Program (CPC) of the YCC was initiated in the mid-1980s, with the selection of Yale as one of the first two NIH-funded Cancer Prevention Research Units (CPRUs) in the United States. In 1993, Dr. Susan Mayne was appointed as Program Leader, and in 1995 she was appointed as Associate Director for Population Sciences of the Center. In 2010, Drs. Melinda Irwin and Yong Zhu were appointed co-Program Leaders, with Dr. Mayne continuing her strong leadership as Associate Director of Population Sciences. The CPC program can thematically be grouped into two primary aims ..or themes. The first theme is population-based studies of lifestyle, environmental, and molecular/genetic factors in the etiology of cancer, with a focus on cancers that have been increasing in Connecticut and elsewhere, and the second major theme is behavioral interventions in cancer prevention/control, which serves to translate findings into prevention and control across the cancer continuum, ranging from primary prevention (tobacco control, exercise, diet) through early detection message framing, to survivorship interventions and finally to end-of-life care. The program has a total of 40 program members representing 4 schools and 11 departments. CPC has a long and rich history of using the State of Connecticut as a population laboratory for cancer prevention and control research. The program is enhanced by its link to the Connecticut Tumor Registry, the oldest population-based tumor registry in the US and an NCI-funded SEER (Surveillance, Epidemiology, and End Results Program) site. In addition, researchers have access to the YCC Rapid Case Ascertainment Shared Resource (RCA), which identifies patients with newly diagnosed cancer throughout the state on a rapid basis, facilitating research projects. Some key CPC findings over the past five years include the strong impact of lifestyle factors (physical activity, diet, and weight) on cancer risk and mortality, and the biological markers/mechanisms linking lifestyle factors to cancer;various smoking cessation interventions for cancer prevention and control;the strong association between indoor tanning and basal cell carcinoma;and associations between circadian factors and several human cancers. The 40 program members have a total of $9.5M in cancer-related research grant funding (annual total costs), of which $9.3M is peer reviewed and $5.5M is NCI-funded. The program is also the host for several training programs. .Program members contributed a total of 525 publications over the last 5-year period, of which 30% are intra-programmatic and 21% are interprogrammatic.

Public Health Relevance

The Cancer Prevention and Control Research Program (CPC) is led by Drs. Melinda Irwin and Yong Zhu and has two themes: (1) population-based studies of lifestyle, environmental, and molecular/genetic factors in the etiology of cancer, and (2) behavioral interventions in cancer prevention and control.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016359-35
Application #
8755630
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
35
Fiscal Year
2014
Total Cost
$17,324
Indirect Cost
$6,919
Name
Yale University
Department
Type
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Ols, Michelle L; Cullen, Jaime L; Turqueti-Neves, Adriana et al. (2016) Dendritic Cells Regulate Extrafollicular Autoreactive B Cells via T Cells Expressing Fas and Fas Ligand. Immunity 45:1052-1065
Gale, Molly; Sayegh, Joyce; Cao, Jian et al. (2016) Screen-identified selective inhibitor of lysine demethylase 5A blocks cancer cell growth and drug resistance. Oncotarget 7:39931-39944
Ducker, Gregory S; Chen, Li; Morscher, Raphael J et al. (2016) Reversal of Cytosolic One-Carbon Flux Compensates for Loss of the Mitochondrial Folate Pathway. Cell Metab 23:1140-53
Adams, Brian D; Wali, Vikram B; Cheng, Christopher J et al. (2016) miR-34a Silences c-SRC to Attenuate Tumor Growth in Triple-Negative Breast Cancer. Cancer Res 76:927-39
Santin, Alessandro D; Bellone, Stefania; Buza, Natalia et al. (2016) Regression of Chemotherapy-Resistant Polymerase ε (POLE) Ultra-Mutated and MSH6 Hyper-Mutated Endometrial Tumors with Nivolumab. Clin Cancer Res 22:5682-5687
de Haydu, Christopher; Black, Jonathan D; Schwab, Carlton L et al. (2016) An update on the current pharmacotherapy for endometrial cancer. Expert Opin Pharmacother 17:489-99
Hollander, Lindsay; Guo, Xiaojia; Velazquez, Heino et al. (2016) Renalase Expression by Melanoma and Tumor-Associated Macrophages Promotes Tumor Growth through a STAT3-Mediated Mechanism. Cancer Res 76:3884-94
Zhao, Siming; Bellone, Stefania; Lopez, Salvatore et al. (2016) Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition. Proc Natl Acad Sci U S A 113:12238-12243
Park, Sin-Aye; Lee, Jong Woo; Herbst, Roy S et al. (2016) GSK-3α Is a Novel Target of CREB and CREB-GSK-3α Signaling Participates in Cell Viability in Lung Cancer. PLoS One 11:e0153075
Stein, Stacey M; James, Edward S; Deng, Yanhong et al. (2016) Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer. Br J Cancer 114:737-43

Showing the most recent 10 out of 275 publications